The Food and Drug Administration approved the first live, non-replicating vaccine to prevent smallpox and monkeypox on September 24, 2019.
September 24, 2019
FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypoxhttps://t.co/DX25ZG8ziE
— Jordan Schachtel @ dossier.today (@JordanSchachtel) May 18, 2022
The Jynneos Smallpox and Monkeypox Vaccine became the only FDA-approved vaccine for the prevention of monkeypox disease at the time.
With reports of suspected monkeypox outbreaks in multiple European countries, the timing of this vaccine approval is extremely suspicious.
Who warned us about a potential "bioterrorist smallpox pandemic?"
American philanthropist Bill Gates has warned of a "bioterrorist smallpox pandemic" which could arise if we don't learn valuable lessons from Covid-19. pic.twitter.com/lCZH6l5uSK
— TalkTV (@TalkTV) November 4, 2021
The 'cure' for a smallpox-monkeypox 'pandemic' or 'bioterrorist attack' was approved right before COVID insanity consumed the global population.
From the FDA:
“Following the global Smallpox Eradication Program, the World Health Organization certified the eradication of naturally occurring smallpox disease in 1980. Routine vaccination of the American public was stopped in 1972 after the disease was eradicated in the U.S. and, as a result, a large proportion of the U.S., as well as the global population has no immunity,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Therefore, although naturally occurring smallpox disease is no longer a global threat, the intentional release of this highly contagious virus could have a devastating effect. Today’s approval reflects the U.S. government’s commitment to preparedness through support for the development of safe and effective vaccines, therapeutics, and other medical countermeasures.”
Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection. This vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. if needed.
Smallpox, which is caused by the variola virus, emerged in human populations thousands of years ago and is a highly contagious and often fatal infectious disease. A person infected with smallpox typically develops a rash characterized by raised pocks on the face and body. The smallpox virus is spread through saliva and droplets from the respiratory tract or by direct or indirect contact with the virus as it is shed from skin lesions. The virus can also be spread through other body fluids and contaminated clothing or bed linen. If a person is infected with smallpox and they are in close contact with others, the virus can spread quickly.
Monkeypox, which does not occur naturally in the U.S., is a rare disease caused by infection with monkeypox virus, which causes symptoms similar to, but milder than, smallpox. Monkeypox begins with fever, headache, muscle aches and exhaustion and can be fatal, even though it is typically milder than smallpox. It is transmitted to people from various wild animals, such as rodents and primates. In 2003, the U.S. experienced an outbreak of monkeypox, which was the first time human monkeypox was reported outside of Africa.
The CDC also has info on the Jynneos smallpox-monkeypox vaccine:
JYNNEOSTM is administered as a live virus that is non-replicating. It is administered as two subcutaneous injections four weeks apart. There is no visible “take” and as a result, no risk for spread to other parts of the body or other people. People who receive JYNNEOS TM are not considered vaccinated until they receive both doses of the vaccine.
Here is the package insert for the Jynneos vaccine.